TMO — THERMO FISHER SCIENTIFIC INC.

NYSE · Unknown · Unknown · CIK 97745 ·
Last close
$469.35
Market Cap
$174.42B
52W High
$537.87
52W Low
$434.83
ADV30
2,421,762
Next earnings
2026-07-22
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 11,005,000,000 4,430,000,000 1,913,000,000 1,651,000,000 113,281,000,000 3,254,000,000 61,220,000,000
Dec 2025 12,215,000,000 5,011,000,000 2,303,000,000 1,964,000,000 110,343,000,000 9,852,000,000 56,807,000,000
Sep 2025 11,122,000,000 4,583,000,000 2,075,000,000 1,616,000,000 103,020,000,000 1,982,000,000 51,866,000,000
Jun 2025 10,854,000,000 4,408,000,000 1,916,000,000 1,617,000,000 101,230,000,000 4,576,000,000 50,628,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$8,290,000,000
Investing CF
$-12,483,000,000
Financing CF
$2,995,000,000
CapEx
$-1,539,000,000
Dividends Paid
$-649,000,000
Buybacks
$-4,000,000,000
EPS Diluted TTM
$18.19
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$60,632,000,000
Inventory
$5,496,000,000
Receivables
$10,888,000,000
ST Investments
$2,000,000
EBIT TTM
$8,892,000,000
Pretax Income TTM
$7,422,000,000
Interest Exp TTM
$1,470,000,000
Analysts
24

Yahoo Snapshot (yfinance, live)

Total Revenue
$45,197,000,704
EBITDA
$11,296,000,000
Free Cash Flow
$5,520,625,152
Enterprise Value
$214,453,534,720
Total Cash
$3,256,000,000
Total Debt
$43,161,001,984
Shares Out
371,621,465
Trailing EPS
$18.21
Book Value
$141.96
ROE
13.5%
ROA
5.0%
Div Yield
0.40%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 44,557,000,000 8,110,000,000 6,704,000,000 110,343,000,000 56,807,000,000 7,818,000,000
Dec 2024 42,879,000,000 7,717,000,000 6,335,000,000 97,321,000,000 47,649,000,000 8,667,000,000
Dec 2023 42,857,000,000 7,318,000,000 5,995,000,000 98,726,000,000 51,884,000,000 8,406,000,000
Dec 2022 44,915,000,000 8,507,000,000 6,950,000,000 97,154,000,000 53,006,000,000 9,154,000,000

TTM Snapshot

Revenues TTM
$41,179,000,000
NetIncome TTM
$6,742,000,000
OpCashFlow TTM
$0
Assets (Latest)
$97,321,000,000
Forward EPS
$27.25

Max Pain — expiry 2026-09-18

max pain strike: $500.00 · spot: $491.35 · call oi: 7,521 · put oi: 4,756
Expected Move to 2026-09-18: ±$66.20 (13.47%) — implied range $425.15$557.55 · ATM straddle on $490.00 strike

News headlines (Yahoo Finance, 1h cache)

[Latest] Global Density Gradient Media Market Size/Share Worth USD 5.3 Billion by 2035 at a 11.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growt
2026-06-24 16:30 · Yahoo
Is Thermo Fisher Scientific Inc. (TMO) a Top Life Sciences Tools Stock After New Analyst Coverage?
2026-06-24 13:26 · Yahoo
Buy Honeywell Stock Before The Split?
2026-06-24 12:59 · Yahoo
Nvidia Targets a $300 Billion Pharma Market
2026-06-23 17:23 · Yahoo
Global Decentralized Clinical Trials Market Size/Share Worth USD 38.3 Billion by 2035 at a 14.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth
2026-06-22 19:30 · Yahoo
Thermo Fisher Scientific Showcases New Capabilities Across Manufacturing, Clinical Development and AI-Enabled Research at BIO International 2026
2026-06-22 12:30 · Yahoo
Global Automated Liquid Handling Systems Market Size/Share Worth USD 6.9 Billion by 2035 at a 9.8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Grow
2026-06-19 02:30 · Yahoo
3 Reasons TMO is Risky and 1 Stock to Buy Instead
2026-06-18 10:53 · Yahoo
Global Fluorescent In Situ Hybridization Probe Market Size/Share Worth USD 2.27 Billion by 2035 at a 7.9% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentatio
2026-06-17 20:30 · Yahoo
Avantor (AVTR) Gets Underperform Rating From Wolfe Research
2026-06-17 09:59 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.